StreetInsider.com News Articles

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

QUEBEC, Feb. 19, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human metabolic-associated steatohepatitis (MASH) model using PhysioMimix^®Liver-on-a-Chip platform. The study was conducted by CN Bio Innovations, Cambridge, UK.

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Thu, 19 Feb 2026 09:00:00 +0000

Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

Tue, 17 Feb 2026 09:00:00 +0000

QUEBEC, Feb. 17, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced that a proprietary Thykamine™ fingerprint has been formally filed in two recent patent applications and is now a core component of the Company's long-term intellectual property and patent strategy. This fingerprint will be systematically incorporated into all future Thykamine^™-related patent filings.

Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

Tue, 17 Feb 2026 09:00:00 +0000

Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

Tue, 17 Feb 2026 09:00:00 +0000

Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

Tue, 17 Feb 2026 09:00:00 +0000

Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

Tue, 17 Feb 2026 09:00:00 +0000

Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

Tue, 17 Feb 2026 09:00:00 +0000

Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

Tue, 17 Feb 2026 09:00:00 +0000